340B Drug Pricing Program
The AHA and five other groups late Friday expressed continued support for the 340B drug pricing program and strongly encouraged Congress to protect the program as it considers broader changes to the nation’s health care system as part of a legislative package under reconciliation.
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to our nation’s health care system.
HRSA Refers Drug Companies for Enforcement Regarding 340B Community Pharmacy Actions
In comments on OPPS proposed rule, AHA continues to oppose 340B cuts The AHA continues to oppose the Centers for Medicare & Medicaid Services’ deep payments cuts to certain 340B hospitals, the association told the agency as part of its comments on the calendar year 2022 outpatient prospective…
A new report from the Community Oncology Alliance (COA) once again tries to obfuscate the issue of sky-rocketing drug prices by choosing to blame hospitals rather than the drug companies who set the prices and enjoy double-digit profits at the expense of patients and the providers who serve them.
Advocacy Alliance Bulletin
Amici curiae are 37 non-profit state and regional hospital associations. They represent thousands of hospitals and health systems across the United States. Amici and their members are committed to improving the health of the communities they serve through the delivery of high-quality, efficient,…
In 1990, Congress enacted the Medicaid Rebate Program, as part of the Omnibus Reconciliation Act of 1990 (Pub. L. No. 101-508).20. This law requires drug companies that choose to participate in Medicaid to give states, which administer Medicaid, discounts comparable to those given to other payers.
Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990 Schedule H, which is publicly available. In 2018, the most recent year for which this information is available, tax-exempt hospitals…
The AHA last week urged congressional leaders to provide temporary relief for any hospitals participating in the 340B Drug Pricing Program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.